MMP408 | 1025716-81-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: MMP408
• 英文别名: (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid；6JP4F7Kkx5；(2S)-2-[[8-(methoxycarbonylamino)dibenzofuran-3-yl]sulfonylamino]-3-methylbutanoic acid
• CAS: 1025716-81-7
• 化学式: C₁₉H₂₀N₂O₇S
• 分子量: 420.443
• InChiKey: MKAIHDAGQJQAHA-KRWDZBQOSA-N

物化性质

• 密度：
  1.440±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  143
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  tert-butyl ((8-((methoxycarbonyl)amino)dibenzo[b,d]furan-3-yl)sulfonyl)-L-valinate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 MMP408
  参考文献：
  名称：

  A Selective Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Chronic Obstructive Pulmonary Disease (COPD): Discovery of (S)-2-(8-(Methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)

  摘要：

  Matrix metalloprotease 12 plays a significant role in airway inflammation and remodeling. Increased expression and production of MMP-12 have-been found in the lung of human COPD patients. MMP408 (14), a potent and selective MMP-12 inhibitor, was derived from a potent matrix metalloprotease 2 and 13 inhibitor via lead optimization and has good physical properties and bioavailability. The compound blocks rhMMP-12-induced lung inflammation in a mouse model and was advanced for further development for the treatment of COPD.

  DOI：

  10.1021/jm900093d

文献信息

• 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACIDS AND THEIR USE
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20170022171A1

  公开（公告）日：2017-01-26

  The present application relates to novel 2,5-disubstituted cyclopentanecarboxylic acid derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory, pulmonary and cardiovascular disorders.

  本申请涉及新型2,5-二取代环戊烷羧酸衍生物，其制备方法，单独或组合使用以治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防呼吸系统、肺部和心血管疾病。
• HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20170121315A1

  公开（公告）日：2017-05-04

  The present application relates to novel heterobicyclically substituted 4-oxobutanoic acid derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of respiratory, pulmonary and cardiovascular disorders.

  本申请涉及新型杂环取代的4-氧代丁酸衍生物，其制备方法，它们单独或组合用于治疗和/或预防疾病的用途，以及它们用于生产治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防呼吸系统、肺部和心血管疾病。
• 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20170114049A1

  公开（公告）日：2017-04-27

  The present application relates to novel 2,5-disubstituted cyclopentanecarboxylic acid derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory, pulmonary and cardiovascular disorders.

  本申请涉及新的2,5-二取代环戊烷羧酸衍生物，其制备方法，其单独或与其他药物联合用于治疗和/或预防疾病的用途，以及用于制备治疗和/或预防呼吸系统、肺部和心血管系统疾病的药物的用途。
• Identification of an Orally Efficacious Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Asthma
  作者：Wei Li、Jianchang Li、Yuchuan Wu、Fabio Rancati、Stefania Vallese、Luca Raveglia、Junjun Wu、Rajeev Hotchandani、Nathan Fuller、Kristina Cunningham、Paul Morgan、Susan Fish、Rustem Krykbaev、Xin Xu、Steve Tam、Samuel J. Goldman、William Abraham、Cara Williams、Joseph Sypek、Tarek S. Mansour

  DOI：10.1021/jm900809r

  日期：2009.9.10

  MMP-12 plays a significant role in airway inflammation and remodeling. Increased expression and production of MMP-12 have been observed in the lungs of asthmatic patients. Compound 27 was identified as a potent and selective MMP-12 inhibitor possessing good physicochemical properties. In pharmacological studies, the compound was orally efficacious in an MMP-12 induced ear-swelling inflammation model in the mouse with a good dose response. This compound also exhibited oral efficacy in a naturally Ascaris-sensitized sheep asthma model showing significant inhibition of the late phase response to allergen challenge. This compound has been considered for further development as a treatment therapy for asthma.
• TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Wyeth

  公开号：EP2074107A2

  公开（公告）日：2009-07-01